Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEANIE L COTE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1467771311
CMS profile
405003
Location
OWOSSO, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$42,657.54

142 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEANIE L COTE

NPI 1467771311 · CMS profile ID 405003

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

OWOSSO, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467771311?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEANIE L COTE, NPI 1467771311, CMS profile ID 405003. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467771311?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JEANIE L COTE, NPI 1467771311, CMS profile ID 405003. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467771311?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JEANIE L COTE, NPI 1467771311, CMS profile ID 405003, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1467771311?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

142 matching records · $42,657.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 142 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–142 of 142.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alnylam Pharmaceuticals Inc. $16.5508/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926076007 CMS
Celgene Corporation $0.9108/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783511 CMS
Lilly USA, LLC $17.6607/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918090201 CMS
Lundbeck LLC $18.8707/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945738559 CMS
ACADIA Pharmaceuticals Inc $22.6307/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952377059 CMS
Celgene Corporation $1.5007/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783499 CMS
E.R. Squibb & Sons, L.L.C. $2,275.0007/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783507 CMS
ABBVIE INC. $9.1207/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890799535 CMS
E.R. Squibb & Sons, L.L.C. $2,275.0007/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783503 CMS
Novartis Pharmaceuticals Corporation $23.4507/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893583969 CMS
Novartis Pharmaceuticals Corporation $7.3507/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893583967 CMS
E.R. Squibb & Sons, L.L.C. $1,137.5007/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783519 CMS
Biohaven Pharmaceutical Holding Company Ltd. $20.3806/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923566147 CMS
E.R. Squibb & Sons, L.L.C. $47.2206/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783505 CMS
Novartis Pharmaceuticals Corporation $3.9506/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893583965 CMS
Celgene Corporation $18.6906/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783485 CMS
Celgene Corporation $26.0006/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783495 CMS
ABBVIE INC. $6.2506/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890799533 CMS
Celgene Corporation $0.6906/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783487 CMS
Takeda Pharmaceuticals U.S.A., Inc. $36.6206/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955613391 CMS
ABBVIE INC. $21.7506/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890799531 CMS
EMD Serono, Inc. $88.2006/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941529711 CMS
Genentech USA, Inc. $15.7506/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950768775 CMS
Genentech USA, Inc. $109.6906/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950768777 CMS
Novartis Pharmaceuticals Corporation $15.4206/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893583963 CMS
Celgene Corporation $0.8806/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783489 CMS
Celgene Corporation $12.5706/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783491 CMS
Biogen, Inc. $23.2706/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923395595 CMS
E.R. Squibb & Sons, L.L.C. $2,275.0006/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783513 CMS
Novartis Pharmaceuticals Corporation $5.6205/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893583961 CMS
ABBVIE INC. $6.2905/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890799529 CMS
E.R. Squibb & Sons, L.L.C. $78.4705/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783515 CMS
Novartis Pharmaceuticals Corporation $18.7505/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893583959 CMS
Celgene Corporation $5.1105/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783481 CMS
Celgene Corporation $5.7205/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783483 CMS
Genentech USA, Inc. $204.8704/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950668447 CMS
Genentech USA, Inc. $389.8404/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950668411 CMS
Genentech USA, Inc. $383.1304/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950668501 CMS
Genentech USA, Inc. $4,290.0004/29/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950668541 CMS
E.R. Squibb & Sons, L.L.C. $875.0004/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932783493 CMS
Novartis Pharmaceuticals Corporation $6.0901/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893583957 CMS
Novartis Pharmaceuticals Corporation $14.8101/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893583955 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,275.10 47
PY2020 $21,937.00 57
PY2021 $26,522.67 38
PY2022 $42,657.54 142
PY2023 $101,378.02 241
PY2024 $108,215.99 202
PY2025 $249,062.06 283

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,493.40 1
PY2025 Principal investigator $321,378.76 70
PY2024 Principal investigator $189,437.17 45
PY2023 Recipient $2,028.52 1
PY2023 Principal investigator $638,958.70 48
PY2022 Principal investigator $98,013.39 30
PY2021 Principal investigator $32,232.73 2
PY2019 Recipient $1,058.64 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $25.00 12/22/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199259
Principal investigator 1 TG Therapeutics, Inc. $25.00 12/19/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199257
Principal investigator 1 TG Therapeutics, Inc. $25.00 12/19/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199261
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,467.54 12/17/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE CENTER
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190307177
Principal investigator 1 TG Therapeutics, Inc. $25.00 12/17/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199255
Principal investigator 1 TG Therapeutics, Inc. $20,775.00 11/30/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199245
Principal investigator 1 TG Therapeutics, Inc. $25.00 11/26/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199253
Principal investigator 1 TG Therapeutics, Inc. $25.00 11/26/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199263
Principal investigator 1 Genentech, Inc. $2,500.00 11/10/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666622
Principal investigator 1 Genentech, Inc. $675.00 11/05/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666619
Principal investigator 1 TG Therapeutics, Inc. $9,150.00 11/01/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199243
Principal investigator 1 TG Therapeutics, Inc. $25.00 10/31/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199251
Principal investigator 1 TG Therapeutics, Inc. $25.00 10/16/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199249
Principal investigator 1 TG Therapeutics, Inc. $25.00 10/15/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199247
Principal investigator 1 TG Therapeutics, Inc. $18,025.00 09/30/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199371
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199203
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199209
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199211
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199213
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199215
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199217
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199219
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/22/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199201
Principal investigator 1 TG Therapeutics, Inc. $9,900.00 08/31/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199369
Principal investigator 1 TG Therapeutics, Inc. $25.00 08/28/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199199
Principal investigator 1 TG Therapeutics, Inc. $25.00 08/28/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199207
Principal investigator 1 Hoffmann-La Roche Limited $1,346.00 08/14/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623573
Principal investigator 1 Hoffmann-La Roche Limited $500.00 08/05/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623568
Principal investigator 1 TG Therapeutics, Inc. $25.00 07/31/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199197
Principal investigator 1 TG Therapeutics, Inc. $25.00 07/31/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199205
Principal investigator 1 TG Therapeutics, Inc. $3,325.00 07/31/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199367
Principal investigator 1 Hoffmann-La Roche Limited $500.00 07/15/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623563
Principal investigator 1 Hoffmann-La Roche Limited $194.00 07/15/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623577
Principal investigator 1 Hoffmann-La Roche Limited $500.00 07/15/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623582
Principal investigator 1 TG Therapeutics, Inc. $25.00 06/16/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199331
Principal investigator 1 TG Therapeutics, Inc. $18,100.00 06/01/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199329
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/30/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199325
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/30/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199347
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/30/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199349
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/30/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199351
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/28/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199323
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/28/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199341
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/28/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199343
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/28/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199345
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/23/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199321
Principal investigator 1 Hoffmann-La Roche Limited $500.00 05/13/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623549
Principal investigator 1 Hoffmann-La Roche Limited $2,308.00 05/13/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623553
Principal investigator 1 Hoffmann-La Roche Limited $2,308.00 05/08/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623557
Principal investigator 1 Genentech, Inc. $2,874.00 05/02/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666609
Principal investigator 1 TG Therapeutics, Inc. $25.00 04/24/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199319
Principal investigator 1 TG Therapeutics, Inc. $25.00 04/22/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199315
Principal investigator 1 TG Therapeutics, Inc. $975.00 04/22/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199317
Principal investigator 1 TG Therapeutics, Inc. $25.00 04/22/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199339
Principal investigator 1 TG Therapeutics, Inc. $25.00 04/21/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199313
Principal investigator 1 TG Therapeutics, Inc. $25.00 04/21/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199337
Principal investigator 1 Genentech, Inc. $77.06 04/17/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666605
Principal investigator 1 Genentech, Inc. $72.27 04/03/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666616
Principal investigator 1 Hoffmann-La Roche Limited $500.00 04/01/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623560
Recipient F. Hoffmann-La Roche AG $2,493.40 03/31/2025 Covered Recipient Physician Switch From Eculizumab to Satralizumab in Aquaporin 4 Immunoglobulin G–Seropositive Neuromyelitis Optica Spectrum Disorder: A Case Series Report No dispute reported 06/30/2026 1211536374
Principal investigator 1 TG Therapeutics, Inc. $6,500.00 03/31/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199307
Principal investigator 1 TG Therapeutics, Inc. $57,764.48 03/24/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199327
Principal investigator 1 Genentech, Inc. $750.00 03/20/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666612
Principal investigator 1 Hoffmann-La Roche Limited $2,980.00 02/20/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623546
Principal investigator 1 Novartis Pharmaceuticals Corporation $126,562.49 02/19/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE CENTER
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190307179
Principal investigator 1 Genentech, Inc. $6,131.00 02/04/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666601
Principal investigator 1 TG Therapeutics, Inc. $9,675.00 02/01/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199305
Principal investigator 1 TG Therapeutics, Inc. $25.00 01/24/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199311
Principal investigator 1 TG Therapeutics, Inc. $25.00 01/24/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199335
Principal investigator 1 Genentech, Inc. $18.92 01/23/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666598
Principal investigator 1 TG Therapeutics, Inc. $25.00 01/08/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199309
Principal investigator 1 TG Therapeutics, Inc. $1,450.00 01/06/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199303